1. Doran MF, Crowson CS, O’Fallon WM et al. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 2002; 29 (8): 1694–7.
2. González-Gay MA, García-Porrúa C, Vázquez-Caruncho M et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999; 26 (6): 1326–32.
3. Gran JT, Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987–94. J Rheumatol 1997; 24 (9): 1739–43.
4. Bernatsky S, Joseph L, Pineau CA et al. Polymyalgia rheumatica prevalence in a population-based sample. Arthritis Rheum 2009; 61 (9): 1264–7.
5. Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001. Ann Rheum Dis 2006; 65 (8): 1093–8.
6. Perfetto F, Moggi-Pignone A, Becucci A et al. Seasonal pattern in the onset of polymyalgia rheumatica. Ann Rheum Dis 2005; 64 (11): 1662–3.
7. Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996; 23 (1): 112–9.
8. Blockmans D, de Ceuninck L, Vanderschueren S et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford) 2007; 46 (4): 672–7.
9. Dasgupta B, Cimmino MA, Maradit-Kremers H et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012; 71 (4): 484–92.
10. Cantini F, Niccoli L, Nannini C et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol 2005; 23 (4): 462–8.
11. Meliconi R, Pulsatelli L, Uguccioni M et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum 1996; 39 (7): 1199–207.
12. Kreiner F, Langberg H, Galbo H. Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum 2010; 62 (12): 3768–75.
13. Demir H, Tanriverdi F, Ozoğul N et al. Evaluation of the hypothalamic-pituitary-adrenal axis in untreated patients with polymyalgia rheumatica and healthy controls. Scand J Rheumatol 2006; 35 (3): 217–23.
14. Бунчук Н.В. Гигантоклеточный артериит и ревматическая полимиалгия. М.: ЭРУС, 1992.
15. Dasgupta B, Borg FA, Hassan N et al.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 2010; 49 (1): 186–90.
16. Dasgupta B, Dolan AL, Panayi GS, Fernandes L. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998; 37 (2): 189–95.
17. van der Veen MJ, Dinant HJ, van Booma-Frankfort C et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996; 55 (4): 218–23.
18. Caporali R, Cimmino MA, Ferraccioli G et al.; Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004; 141 (7): 493–500.
19. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45 (2): 136–8.
20. Salvarani C, Macchioni P, Manzini C et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007; 146 (9): 631–9.

Ю.А.Олюнин

ФГБУ Научно-исследовательский институт ревматологии им. В.А.Насоновой РАМН, Москва